Owens & Minor (NYSE:OMI) Stock, Quote.Headers.trade-ideas

Owens & Minor

Owens & Minor Inc distributes consumable medical supplies to a variety of providers. The business is under two segments: Products & Healthcare Services and Patient Direct. The Products & Healthcare Services segment manufactures and sources medical surgical products through its production and kitting operations and provides medical supplies and solutions for the prevention of healthcare-associated infections across the acute and alternate site channels. The Patient Direct segment provides delivery of disposable medical supplies sold directly to patients and home health agencies. Majority of the revenue is generated from Products & Healthcare Services segment.

Earnings

Earnings Beats

Large Cap

News

Health Care

Small Cap

Management

Markets

Analyst Ratings

Trading Ideas

General

AXGN

Owens &amp; Minor, Inc. (NYSE: OMI) has announced a partnership with Google Cloud, owned by the parent holding company, Alphabet to enhance the existing capabilities of its cloud-based clinical inventory management system, QSight.

Owens &amp; Minor Stock to Gain From New Collaboration With Google Cloud

PAHC

Cardinal Health, Inc. (NYSE: CAH) is scheduled to report fourth-quarter fiscal 2024 results on Aug 14, before the opening bell.

What&#39;s in Store for Cardinal Health in Q4 Earnings?

Mid Cap

ADTN

AMCX

BALY

After spiking in the first quarter of 2024, inflation has been weakening from April. In fact, per the June data, the annual rate of inflation dropped to its lowest level in more than two years, raising hopes of a rate cut in September. This bodes well as low interest rates improve consumer outlays, decrease the cost of borrowings and, in turn, boost economic growth.

5 Stocks Loved by Brokers Worth Watching Currently

Owens & Minor Inc

Singular Genomics Systems, Inc. - Common Stock

Singular Genomics Systems Inc

Omid Holdings Inc

OMINECA MINING & MTLS ORD by Omineca Mining & Metals Ltd.

Omineca Mining and Metals Ltd

Owens &amp; Minor, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/omi#NYSE">OMI</a>) has announced a partnership with Google Cloud, owned by the parent holding company, Alphabet&nbsp;to enhance the existing capabilities of its cloud-based clinical inventory management system, QSight. The collaboration will combine the company&#39;s expertise in optimizing the healthcare supply chain with Google Cloud&#39;s Vertex AI platform, to tackle the modern supply chain management complexities and support the patients more effectively.
The latest development demonstrates the progress Owens &amp; Minor has been making toward its strategic goals for the Products &amp; Healthcare Services segment.
Following the news, shares of OMI edged up 0.2% to $14.42 at Tuesday&#39;s close. By staying at the forefront of technology, including making investments with one of the most renowned innovators in the market, the company consistently delivers value to its customers and improves clinician efficiency. We expect the market sentiment on OMI stock to stay positive around this development.
<h2>Significance of OMI&#39;s New Partnership</h2>
The implications of inefficient inventory management in healthcare can extend beyond the stockroom and into the operating room. This includes the risks of expired products being used in patient care and loss of inventory if products expire before. There is also an increasing pressure to deliver high-quality care while managing costs and optimizing efficiency &mdash; with less support from clinical staff.
However, traditional clinical inventory management systems often lack the real-time visibility and predictive capabilities to oversee the complex healthcare supply chains, leading to increasing costs and higher workloads for clinical staff.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/dd/77474.jpg?v=1748561454" />
Image Source: Zacks Investment Research
The partnership between Owens &amp; Minor and Google Cloud aims to focus on enhancing QSight&#39;s ability to help hospitals and health systems optimize how they manage the thousands of medical-grade supplies, high-value surgical implants and human tissue products required for patient care. The company will also lay the foundation for future platform and service innovations with the potential to improve the QSight customer experience.
<h2>Favorable Industry Prospects for Owens &amp; Minor</h2>
A report by Research and Markets&nbsp;valued the healthcare inventory management software market at $331.5 million in 2021 and forecasts it to see a compound annual rate of 8.9% through 2028.
The rising complexity of the healthcare supply chain, such as worldwide sourcing, diversified product portfolios, regulatory constraints, and the demand for real-time monitoring, have increased the need for sophisticated inventory management systems. Healthcare organizations are implementing advanced inventory management solutions that provide greater visibility, automation and analytics.
<h2>Other Major Developments Within OMI</h2>
In July 2024, Owens &amp; Minor announced a definitive agreement to acquire Rotech Healthcare Holdings, Inc., a home medical equipment provider based in the United States, for $1.36 billion in cash. The acquisition directly aligns with the company&#39;s broader strategy to expand into the fast-growing home-based care space. In addition, it also bolsters its Patient Direct product offerings through expansion across a complementary portfolio including Respiratory, Sleep Apnea, Diabetes and Wound Care.
<h2>OMI Stock Price Performance</h2>
In the past year, Owens &amp; Minor shares have plunged 10.8% against the industry&#39;s 18.4% growth.
<h2>OMI Estimate Trend and EPS Surprise History</h2>
In the past 30 days, estimates for Owens &amp; Minor&#39;s 2024 earnings have remained constant at $1.57 per share. The company beat estimates in each of the trailing four quarters, the average surprise being 11.1%.
<h2>OMI&#39;s Zacks Rank and Top MedTech Stocks</h2>
Owens &amp; Minor currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are Boston Scientific (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bsx#NYSE">BSX</a>) and AxoGen (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/axgn#NASDAQ">AXGN</a>), each carrying a Zacks Rank #2 (Buy) at present.
Boston Scientific&#39;s shares have risen 55.9% in the past year. Estimates for the company&#39;s earnings per share have remained constant at $2.40 in 2024 and $2.71 in 2025 in the past 30 days. BSX&#39;s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 7.2%. In the last reported quarter, it posted an earnings surprise of 6.9%.
Estimates for AxoGen&#39;s 2024 loss per share have remained constant at 1 cent in the past 30 days. Shares of the company have surged 141.4% in the past year compared with the industry&#39;s growth of 15.7%. AXGN&#39;s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 96.5%. In the last reported quarter, it delivered an earnings surprise of 200%.
<a href="https://www.zacks.com/stock/news/2335232/owens-minor-stock-to-gain-from-new-collaboration-with-google-cloud?cid=CS-BENZ-FT-analyst_blog|company_news_medical_sector-2335232">To read this article on Zacks.com click here.</a>

Owens & Minor Stock to Gain From New Collaboration With Google Cloud

By partnering with Google Cloud, Owens &amp; Minor will strengthen QSight&#39;s existing inventory management capabilities while laying the foundation for future platform and service innovations with the potential to dramatically improve the QSight customer experience.

GOOG

GOOGL

Owens & Minor Enters New Partnership With Google Cloud; Collaboration Will Enhance Existing QSight Capabilities

JP Morgan analyst Lisa Gill maintains Owens &amp; Minor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OMI#NYSE">OMI</a>) with a Underweight and lowers the price target from $22 to $18.

Price Target

JP Morgan Maintains Underweight on Owens & Minor, Lowers Price Target to $18

Cardinal Health, Inc.&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cah#NYSE">CAH</a>) is scheduled to report fourth-quarter fiscal 2024 results on Aug 14, before the opening bell.
In the last reported quarter, the company delivered an earnings surprise of 6.67%. CAH&#39;s earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, delivering an average surprise of 12.91%.
<h3>Q4 Estimates</h3>
For the fiscal fourth quarter, the consensus mark for earnings is pegged at $1.72 per share, indicating an improvement of 10.9% from the prior-year quarter&#39;s reported figure. The same for revenues is pinned at $58.72 billion, implying growth of 9.9% year over year.
<h3>Factors to Note</h3>
From the fiscal third quarter of 2024, Cardinal Health started reporting its results under new operating segments &mdash; Pharmaceutical and Specialty solutions, Global Medical Products and Distribution (GMPD) segment, nuclear at-Home and OptiFreight.
The third quarter of fiscal 2024 witnessed an uptick in revenues in the Pharmaceutical segment, which amounted to approximately $50.7 billion, up 9% on a year-over-year basis. The Pharmaceutical Distribution and Specialty Solutions segment&#39;s performance highlighted branded pharmaceutical sales growth from existing customers. The segment&#39;s profit increased 4% during the fiscal third quarter. This momentum is likely to have continued in the&nbsp;fiscal fourth quarter&nbsp;as well. Moreover, the rising demand for GLP-1 medications is likely to have acted as a tailwind.
Higher contributions from brand and specialty products, as well as the effectiveness of the generics program, drove the positive outcome of the pharmaceutical segment in the last reported quarter. This trend is likely to have continued in the to-be-reported quarter as well.
Medical segment&#39;s revenues grew 4% year over year in the last reported quarter, driven by growth in at-Home Solutions and GMPD. The segment&#39;s profit was $20 million in the fiscal third quarter. This upside was driven by an improvement in net inflationary impacts, including mitigation initiatives, which are likely to have boosted the medical segment&#39;s results in the fiscal fourth quarter as well.
In March 2024, Cardinal Health completed the acquisition of Specialty Networks, which is likely to expand the company&#39;s offerings with physicians in the areas of urology, GI, and rheumatology. Specialty Networks is providing a proven platform in PPS analytics that the company is likely to further invest in fiscal 2025 and look to extend to other therapeutic areas such as oncology.
Per the third-quarter earnings call, CAH&#39;s integration of Specialty Networks is underway, and the reaction from the providers the company serves has been extremely encouraging. The platform&#39;s insight generation capabilities for clinicians are robust, which is likely to accelerate CAH&#39;s upstream data and research opportunities with biopharma manufacturers. The company is expected to provide further updates in this regard in the to-be-reported quarter.
The company announced its new distribution center being built in South Carolina, which, per management, features the fastest order fulfillment system per square foot in the market. The center is scheduled to open by early next fiscal year. New distribution centers are likely to aid the company&#39;s supply chain, thus improving revenues. Cardinal Health is likely to provide further updates in this regard in the to-be-reported quarter.
<h3>What the Zacks Model Unveils</h3>
Our proven model does not conclusively predict an earnings beat for Cardinal Health this time around. The combination of a positive&nbsp;Earnings ESP&nbsp;and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. This is not the case here, as you will see below.
Earnings ESP:&nbsp;Earnings ESP, which represents the difference between the Most Accurate Estimate and the Zacks Consensus Estimate, is -0.17%.
Zacks Rank:&nbsp;Cardinal Health currently carries a Zacks Rank #3.
<div class="chart_embed">
<h3>Cardinal Health, Inc. Price and EPS Surprise</h3>
<img alt="Cardinal Health, Inc. Price and EPS Surprise" src="https://staticx-tuner.zacks.com/images/charts/50/1723470107.png" style="height:263px; width:544px" title="" />
Cardinal Health, Inc. price-eps-surprise | Cardinal Health, Inc. Quote
</div>
<h3>Stocks to Consider</h3>
Here are a few other medical stocks worth considering, as these also have the right combination of elements to beat on earnings this reporting cycle.
Phibro Animal Health&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pahc#NASDAQ">PAHC</a>) has an Earnings ESP of +0.99% and a Zacks Rank of 2 at present.
The stock has risen 59.5% year to date. PAHC&#39;s earnings beat estimates in the last reported quarter. It has a trailing four-quarter average negative earnings surprise of 2.30%.
Owens &amp; Minor&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/omi#NYSE">OMI</a>) has an Earnings ESP of +1.54% and a Zacks Rank of 2 at present.
The stock has lost 14.6% year to date. OMI&#39;s earnings beat estimates in the last reported quarter. It has a trailing four-quarter average earnings surprise of 11.99%.
ResMed&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/rmd#NYSE">RMD</a>) has an Earnings ESP of +2.85% and a Zacks Rank of 3 at present.
The stock has risen 16% year to date. RMD&#39;s earnings beat estimates in the last reported quarter. It has a trailing four-quarter average earnings surprise of 2.81%.
<a href="https://www.zacks.com/stock/news/2320761/what-s-in-store-for-cardinal-health-cah-in-q4-earnings?cid=CS-BENZ-FT-analyst_blog|earnings_preview-2320761">To read this article on Zacks.com click here.</a>

What's in Store for Cardinal Health in Q4 Earnings?

Barclays analyst Steven Valiquette maintains Owens &amp; Minor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OMI#NYSE">OMI</a>) with a Equal-Weight and lowers the price target from $23 to $18.

Barclays Maintains Equal-Weight on Owens & Minor, Lowers Price Target to $18

After spiking in the first quarter of 2024, inflation has been weakening from April. In fact, per the June data, the annual rate of inflation dropped to its lowest level in more than two years, raising hopes of a rate cut in September. This bodes well as low interest rates improve consumer outlays, decrease the cost of borrowings and, in turn, boost economic growth.
Additionally, second-quarter quarter earnings have been impressive so far, with many companies reporting better-than-expected earnings per share. Given this brightening scenario, investors would like to design a winning portfolio of stocks for impressive returns. One way to do so is by following broker advice. Stocks like ADTRAN (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/adtn#NASDAQ">ADTN</a>), Bread Financial (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bfh#NYSE">BFH</a>), Owens &amp; Minor (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/omi#NYSE">OMI</a>), Bally&#39;s Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/baly#NYSE">BALY</a>) and AMC Networks (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/amcx#NASDAQ">AMCX</a>) are worth monitoring.
We have designed a screen to shortlist stocks based on improving broker recommendations and upward revisions in earnings estimates over the past four weeks. Also, since the price/sales ratio is a strong complementary valuation metric in the presence of broker information, it has been included. The price/sales ratio takes care of the company&#39;s top line, making the strategy a well-rounded one.
<h3>Screening Criteria</h3>
# (Up- Down Rating)/ Total (4 weeks) =Top #75&nbsp;(This gives the list of the top 75 companies that have witnessed net upgrades over the last 4 weeks).
% change in Q (1) est. (4 weeks) = Top #10&nbsp;(This gives the top 10 stocks that have witnessed earnings estimate revisions over the past 4 weeks for the upcoming quarter).
Price-to-Sales = Bot%10&nbsp;(The lower the ratio, the better. Companies meeting this criterion are in the bottom 10% of our universe of over 7,700 stocks with respect to this ratio).
Price greater than 5&nbsp;(as a stock trading below $5 will not likely create significant interest for most of the investors).
Average Daily Volume greater than 100,000 shares over the last 20 trading days&nbsp;(Volume has to be significant to ensure that these are easily traded).
Market value ($ mil) = Top #3000&nbsp;(This gives us stocks that are the top 3000 in terms of market capitalization).
Com/ADR/Canadian= Com&nbsp;(This takes out the ADR and Canadian stocks).
Here are five of the 10 stocks that made it through the screen:
ADTRAN is poised to capitalize on its strengths in ultra-broadband and fiber-to-the-home solutions along with Software-Defined or SD access and Ethernet passive optical network solutions. Its global leadership in SD access is likely to ensure a steady stream of revenues as it helps clients reduce costs and accelerate service delivery and deployment.
ADTN currently carries a Zacks Rank #3 (Hold). The Zacks Consensus Estimate for ADTN&#39;s 2024 earnings has remained stable over the past 60 days.
Bread Financial is based in Columbus, OH. The company continues to benefit from data-driven marketing strategies. Solid receivables growth in Card Services should drive its top line. Acquisitions and divestitures will aid the company in growing inorganically and expanding its international footprint.
Over the past 60 days, the Zacks Consensus Estimate for BFH&#39;s current-quarter earnings has increased 31%. Bread Financial currently carries a Zacks Rank #3.
Owens &amp; Minor is a global healthcare solutions company. Shares of this Zacks Rank #3 company have gained 28% in the past month. In 2024, the company&#39;s earnings are expected to witness growth of 14.7% from 2023 actuals.
The Zacks Consensus Estimate for Owens &amp; Minor&#39;s 2024 earnings is currently pegged at $1.56 per share, indicating a 2% upward revision over the past 30 days. OMI&#39;s earnings surpassed estimates in each of the last four quarters, with an average beat of 11.1%.
Bally&#39;s shares have been moving north lately following news of its merger agreement with Standard General L.P., valued at approximately $4.6 billion. The agreement involves combining Bally&#39;s with The Queen Casino &amp; Entertainment Inc., a regional casino operator.&nbsp;
Over the past 60 days, the Zacks Consensus Estimate for BALY&#39;s current-quarter earnings has increased 57%. The company currently carries a Zacks Rank #2 (Buy).
AMC Networks is benefiting from a rising focus on high-quality programming and strong partnerships, which, in turn, are driving subscriber growth and ad revenues.
Over the past 60 days, the Zacks Consensus Estimate for AMCX&#39;s current-quarter earnings has remained stable at $1.38 per share. The radio and television broadcast company currently carries a Zacks Rank #3.
Disclosure: Officers, directors and/or employees of Zacks Investment Research may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material. An affiliated investment advisory firm may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material.
<a href="https://www.zacks.com/stock/news/2315768/5-stocks-loved-by-brokers-worth-watching-currently?cid=CS-BENZ-FT-analyst_blog|rw-2315768">To read this article on Zacks.com click here.</a>

WIIM

Owens & Minor shares are trading lower. The company reported Q2 financial results.

On Friday,&nbsp;Owens &amp; Minor Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OMI#NYSE">OMI</a>) reported that the second quarter of 2024 adjusted EPS of $0.36, double the $0.18 reported a year ago, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $0.33</a>.
The company reported sales of $2.671 billion, up 4% year-over-year, almost in line with the <a target="_blank" href="https://www.benzinga.com/pressreleases/24/08/b40125902/owens-minor-reports-second-quarter-2024-financial-results" rel="noreferrer noopener">consensus of $2.646 billion</a>.
Patient Direct revenue of $660 million, up 4% compared to the second quarter of 2023, driven by continued strong growth in diabetes and sleep supplies.
Related: <a target="_blank" href="https://www.benzinga.com/news/earnings/24/07/39914439/healthcare-logistics-service-firm-owens-minor-to-buy-home-based-care-equipment-firm-for-1-4b-sees-b" rel="noreferrer noopener">Healthcare Logistics Service Firm Owens &amp; Minor To Buy Home-Based Care Equipment Firm For $1.4B, Sees Better Than Expected Q2 Earnings</a>.
Products &amp; Healthcare Services revenue of $2.0 billion, up 4% compared to the second quarter of 2023, driven by strong same-store sales and new wins in the Medical Distribution division.
Operating income of $20.3 million and adjusted operating income of $76.3 million increased by 87% and 23%, respectively, in the second quarter of 2024.
Adjusted EBITDA increased 12% to $127 million, with an operating cash flow of $116 million for the second quarter of 2024.
&#8220;Our second-quarter performance is consistent with our expectations, as we are in the early stages of implementing our long-term strategy discussed at Investor Day in December 2023. Our previous investments in our Products &amp; Healthcare Services segment yielded positive results and generated top-line growth in our Medical Distribution division. Our Patient Direct segment performed in line with our expectations, and we expect the segment to benefit from seasonality and recent organic investments during the back half of the year,&#8221; said Edward Pesicka, President &amp; CEO.
Guidance:&nbsp;Owens &amp; Minor reaffirms 2024 revenue guidance of $10.5 billion-$10.9 billion versus the <a target="_blank" href="https://www.benzinga.com/news/earnings/24/05/38620005/whats-going-on-with-healthcare-logistics-giant-owens-stock-on-friday" rel="noreferrer noopener">consensus of $10.665 billion</a>.
The company&nbsp;expects&nbsp;2024 adjusted EPS of $1.40-$1.70 versus the consensus of&nbsp;$1.55.
Price Action:&nbsp;OMI stock was trading lower by 3.90% to $15.78 premarket at the last check on Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40109789/labcorps-stock-soars-after-q2-performance-analyst-highlights-strong-position-in-hea" target="_blank" rel="noreferrer noopener">LabCorp&#8217;s Stock Soars After Q2 Performance, Analyst Highlights Strong Position In Healthcare Sector</a>.</li>
</ul>

Guidance

Movers

Healthcare Logistics Provider Owens & Minor Calls Q2 Performance Consistent With Expectations, Reiterates Annual Guidance

Owens & Minor Reaffirms 2024 Guidance With Sales Of $10.5B-$10.9B And Adjusted EPS Of $1.40-$1.70, Versus Consensus Of $10.665B And $1.55, Respectively

Owens & Minor Q2 2024 Adj. EPS $0.36 Beats $0.33 Estimate, Sales $2.671B Beat $2.646B Estimate

On Tuesday, Owens &amp; Minor Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OMI#NYSE">OMI</a>) agreed to acquire Rotech Healthcare Holdings, Inc., a privately held home-based care business headquartered in Orlando, Florida, <a target="_blank" href="https://www.benzinga.com/pressreleases/24/07/b39901327/owens-minor-inc-signs-definitive-agreement-to-acquire-rotech-healthcare-holdings-inc-for-1-36-bill" rel="noreferrer noopener">for $1.36 billion in cash</a>.
Given anticipated tax benefits of approximately $40 million from the transaction, the net purchase price is approximately $1.32 billion, representing approximately a 6.3x multiple of LTM EBITDA, excluding synergies.
Rotech provides home medical equipment in the U.S. The company has over 4,200 employees and provides products and services in 46 states through approximately 325 operating locations.
Rotech generated approximately $750 million of revenue and an EBITDA margin of nearly 30% in 2023.
The deal strengthens Owen &amp; Minor&#8217;s Patient Direct product offerings through expansion&nbsp;across a complementary portfolio and accelerates the growth&nbsp;path&nbsp;for the Patient Direct segment as outlined at the December 2023 Investor Day to achieve $5 billion in revenue by 2028.
The transaction provides a significant synergy opportunity of approximately $50 million by the end of year three, with further upside potential and prospects for additional revenue synergies in the near and long term.
Owens &amp; Minor also announced selected preliminary financial results for the second quarter of 2024, with revenue of $2.65 billion—$2.67 billion versus a consensus of $2.64 billion.
The healthcare logistics services company sees adjusted EPS of $0.32 &#8211; $0.36 compared <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">to a consensus of $0.31</a>.
In the second quarter of 2024, the company incurred a one-time income tax charge of $17 million ($0.22 per share) due to a recent decision on Notices of Proposed Adjustments from 2020 and 2021, communicated in late June 2024. A related cash payment of $30-$35 million is expected in the second half of 2024. The company anticipates resolving the matter <a target="_blank" href="https://www.benzinga.com/pressreleases/24/07/b39901364/owens-minor-inc-releases-preliminary-second-quarter-2024-financial-results-reaffirms-2024-annual-g" rel="noreferrer noopener">without further financial impact</a>.
For 2024, Owens &amp; Minor reaffirmed its&nbsp;revenue outlook&nbsp;of $10.5 billion-$10.9 billion compared to a consensus of $10.66 billion.
The company continues to see 2024 adjusted EPS of $1.40-$1.70 versus the consensus of $1.53.
Price Action: OMI stock is up 7.38% at $16.44 at last check Tuesday.
Photo via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/07/39909352/cancer-focused-cellectar-biosciences-stock-trades-lower-despite-meeting-goal-in-blood-cancer-stud" target="_blank" rel="noreferrer noopener">Cancer-Focused Cellectar Biosciences Stock Trades Lower Despite Meeting Goal In Blood Cancer Study</a>.</li>
</ul>

Equities

Healthcare Logistics Service Firm Owens & Minor To Buy Home-Based Care Equipment Firm For $1.4B, Sees Better Than Expected Q2 Earnings

Shares of Comcast Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMCSA#NASDAQ">CMCSA</a>) fell sharply during Tuesday's session after the company reported worse-than-expected <a href="https://www.benzinga.com/news/earnings/24/07/39908857/comcasts-q2-earnings-studios-and-theme-parks-pull-revenue-lower-broadband-and-video-subs-fall">second-quarter sales results</a>.
Comcast reported second-quarter revenue decline of 2.7% year-over-year to $29.69 billion, missing the analyst consensus estimate of $30.02 billion.The company reported adjusted EPS of $1.21, beating analyst consensus estimates of $1.12, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Comcast shares declined 6.1% to $37.12 on Tuesday.
Here are some other stocks moving in today&#8217;s mid-day session.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Azitra, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZTR#NYSE">AZTR</a>) shares jumped 529% to $10.19 after the company announced that the U.S. Patent and Trademark Office granted it U.S. Patent No. 12,036,248 for the treatment of atopic dermatitis.</li>
<li>Adial Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADIL#NASDAQ">ADIL</a>) jumped 148% to $2.6299 after the company announced it advanced into the second cohort and commenced dosing for the Pharmacokinetics Study of AD04 for alcohol use disorder.</li>
<li>Salarius Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLRX#NASDAQ">SLRX</a>) gained 111% to $3.2540.</li>
<li>Agape ATP Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATPC#NASDAQ">ATPC</a>) shares climbed 67% to $0.2390.</li>
<li>Smart for Life, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMFL#NASDAQ">SMFL</a>) rose 45% to $2.7950.</li>
<li>Dermata Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRMA#NASDAQ">DRMA</a>) gained 43% to $2.41.</li>
<li>Regencell Bioscience Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) jumped 36.5% to $4.60.</li>
<li>Volato Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOAR#NYSE">SOAR</a>) gained 33.5% to $0.6385 after jumping around 20% on Monday.</li>
<li>Frequency Electronics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FEIM#NASDAQ">FEIM</a>) shares climbed 30% to $13.11 following fourth-quarter earnings. Also, the company declared a $1.00 special cash dividend.</li>
<li>Mammoth Energy Services, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TUSK#NASDAQ">TUSK</a>) gained 26% to $4.42 after the company announced its subsidiary, Cobra Acquisitions, entered into a release and settlement agreement with the Puerto Rico Electric Power Authority.</li>
<li>iClick Interactive Asia Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLK#NASDAQ">ICLK</a>) rose 23.5% to $2.05.</li>
<li>1847 Holdings LLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EFSH#NYSE">EFSH</a>) jumped 19.3% to $2.90.</li>
<li>Milestone Scientific Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MLSS#NYSE">MLSS</a>) gained 17.5% to $1.02 after the company announced the Medicare price assignment for its CompuFlo Epidural System.</li>
<li>Staffing 360 Solutions, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAF#NASDAQ">STAF</a>) gained 16% to $2.1493.</li>
<li>Kiniksa Pharmaceuticals International, plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KNSA#NASDAQ">KNSA</a>) rose 16% to $24.81 after the company reported better-than-expected second-quarter sales results and raised its FY24 net product revenue guidance.</li>
<li>Aeva Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AEVA#NYSE">AEVA</a>) gained 15.1% to $3.6713.</li>
<li>Spotify Technology S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPOT#NYSE">SPOT</a>) jumped 12.7% to $333.02 following second-quarter earnings.</li>
<li>NuScale Power Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMR#NYSE">SMR</a>) gained 11.8% to $12.34.</li>
<li>PureCycle Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCT#NASDAQ">PCT</a>) rose 11.8% to $6.90.</li>
<li>MSCI Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSCI#NYSE">MSCI</a>) gained 11.1% to $561.96 following better-than-expected second-quarter financial results.</li>
<li>Crown Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCK#NYSE">CCK</a>) rose 8.5% to $84.04 after the company reported better-than-expected second-quarter earnings and raised its FY24 EPS guidance above estimates.</li>
<li>MakeMyTrip Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMYT#NASDAQ">MMYT</a>) gained 8% to $96.75 following better-than-expected quarterly earnings.</li>
<li>Owens &amp; Minor, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OMI#NYSE">OMI</a>) gained 8% to $16.51 as the company released preliminary second quarter 2024 financial results and signed a definitive agreement to acquire Rotech Healthcare for $1.36 billion in cash.</li>
<li>Mesoblast Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MESO#NASDAQ">MESO</a>) shares surged 8% to $8.15. Mesoblast recently started enrollment in Phase 3 trial of Rexlemestrocel-L for chronic low back pain.</li>
<li>Pentair plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PNR#NYSE">PNR</a>) climbed 7.7% to $86.19 after the company reported better-than-expected second quarter financial results and revised its FY24 adjusted EPS guidance above estimates.</li>
<li>Danaher Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) gained 7.4% to $269.35 after the company reported better-than-expected second quarter earnings.</li>
<li>GE Aerospace (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GE#NYSE">GE</a>) gained 6.4% to $173.21 after the company reported better-than-expected second quarter adjusted EPS and raised its FY24 outlook.</li>
<li>SAP SE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAP#NYSE">SAP</a>) rose 6% to $0.2390 after the company reported second-quarter financial results.</li>
<li>Zions Bancorporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZION#NASDAQ">ZION</a>) gained 5.4% to $52.12 after posting better-than-expected quarterly results on Monday.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Jaguar Health, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAGX#NASDAQ">JAGX</a>) shares dipped 65% to $1.50 after the company announced its phase 3 OnTarget trial results for Crofelemer did not meet its primary endpoint.</li>
<li>TransCode Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAZ#NASDAQ">RNAZ</a>) dipped 62.2% to $0.2999 after the company announced a proposed public offering.</li>
<li>Fly-E Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLYE#NASDAQ">FLYE</a>) tumbled 59.2% to $2.60.</li>
<li>MIRA Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIRA#NASDAQ">MIRA</a>) shares dipped 50.3% to $2.4636. MIRA Pharmaceuticals shares jumped 627% on Monday after the company announced new preclinical study results for its novel oral ketamine analog, Ketamir-2.</li>
<li>CareMax, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMAX#NASDAQ">CMAX</a>) shares fell 38.3% to $3.1851 after surging 228% on Monday.</li>
<li>Selina Hospitality PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLNA#NASDAQ">SLNA</a>) dipped 32.4% to $0.0250.</li>
<li>PS International Group Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSIG#NASDAQ">PSIG</a>) fell 32.2% to $1.83.</li>
<li>Exicure, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XCUR#NASDAQ">XCUR</a>) fell 31.1% to $0.3440.</li>
<li>Cellectar Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLRB#NASDAQ">CLRB</a>) dipped 26.2% to $2.23. The company announced results from its CLOVER WaM pivotal study evaluating iopofosine I 131.</li>
<li>Crown LNG Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGBS#NASDAQ">CGBS</a>) fell 23% to $0.77.</li>
<li>Castellum, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTM#NYSE">CTM</a>) fell 20% to $0.1594. Castellum recently announced a new strategic alliance with Krilla Kaleiwahea.</li>
<li>Netcapital Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCPL#NASDAQ">NCPL</a>) fell 17.3% to $0.0926 after gaining around 8% on Monday.</li>
<li>Medpace Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MEDP#NASDAQ">MEDP</a>) shares declined 16.6% to $364.00 after the company reported mixed second-quarter financial results and narrowed its FY24 revenue guidance with its midpoint below estimates.</li>
<li>Fitell Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTEL#NASDAQ">FTEL</a>) dipped 15.2% to $16.48.</li>
<li>United Parcel Service, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UPS#NYSE">UPS</a>) fell 13.2% to $126.04 after the company reported worse-than-expected quarterly financial results.</li>
<li>Nukkleus Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUKK#NASDAQ">NUKK</a>) shares fell 10% to $0.4479 after gaining over 55% on Monday.</li>
<li>NXP Semiconductors N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXPI#NASDAQ">NXPI</a>) shares fell 9.5% to $256.55 following mixed second-quarter earnings.</li>
<li>New Fortress Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFE#NASDAQ">NFE</a>) dipped 9.2% to $23.28.</li>
<li>PACCAR Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCAR#NASDAQ">PCAR</a>) fell 8.4% to $99.92 after the company reported worse-than-expected second-quarter financial results.</li>
<li>A. O. Smith Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AOS#NYSE">AOS</a>) declined 8.4% to $81.30. The company reported second-quarter financial results.</li>
<li>WEBTOON Entertainment Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBTN#NASDAQ">WBTN</a>) dipped 7.7% to $22.00.</li>
<li>Polaris Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PII#NYSE">PII</a>) declined 7.2% to $76.23 after the company reported worse-than-expected second-quarter financial results and cut its guidance.</li>
<li>Archrock, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AROC#NYSE">AROC</a>) shares declined 6.9% to $21.76. Archrock commenced public offering of 11 million shares of its common stock and announced plans to acquire Total Operations and Production Services for $983 million in cash and stock.</li>
<li>General Motors Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>) fell 6.1% to $46.52 after the company reported second-quarter financial results. Also, the company announced that it delayed its 2024 Buick EV and pushed its EV pickup plant opening to 2026.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/07/39907957/microsoft-to-rally-around-10-here-are-10-top-analyst-forecasts-for-monday">Microsoft To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Tuesday</a></li>
</ul>

Intraday Update

ADIL

AEVA

AROC

ATPC

AZTR

CGBS

CLRB

CMAX

CMCSA

DRMA

EFSH

FEIM

FLYE

FTEL

ICLK

JAGX

KNSA

MEDP

MESO

MIRA

MLSS

MMYT

MSCI

NCPL

NUKK

NXPI

PCAR

PSIG

RNAZ

SLNA

SLRX

SMFL

SOAR

SPOT

STAF

TUSK

WBTN

XCUR

ZION

Why Comcast Shares Are Trading Lower By 6%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

Owens & Minor shares are trading higher after the company reported preliminary Q2 financial results and issued FY24 guidance. The company entered into a definitive agreement to acquire Rotech Healthcare Holdings.

U.S. stocks were mixed, with the Dow Jones index falling around 50 points on Tuesday.
Shares of Danaher Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) rose sharply during Tuesday's session after the company reported better-than-expected <a href="https://www.benzinga.com/news/earnings/24/07/39907956/life-science-giant-danahers-q2-earnings-beat-estimates-on-sustained-positive-momentum-in-bioprocess">second quarter earnings</a>.
Danaher's second quarter sales decreased 3% year-over-year to $5.743 billion, beating the consensus of $5.59 billion. Danaher reported second-quarter adjusted EPS of $1.72, beating the consensus of $1.57, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro.</a>
Danaher shares gained 7.4% to $269.35 on Tuesday.
Here are some other big stocks recording gains in today&#8217;s session.
<ul>
<li>Kiniksa Pharmaceuticals International, plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KNSA#NASDAQ">KNSA</a>) shares jumped 16% to $24.81 after the company reported better-than-expected second-quarter sales results and raised its FY24 net product revenue guidance.</li>
<li>Spotify Technology S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPOT#NYSE">SPOT</a>) gained 12.7% to $333.02 following second-quarter earnings.</li>
<li>NuScale Power Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMR#NYSE">SMR</a>) surged 11.8% to $12.34.</li>
<li>PureCycle Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCT#NASDAQ">PCT</a>) gained 11.8% to $6.90.</li>
<li>KKR Real Estate Finance Trust Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KREF#NYSE">KREF</a>) surged 11.2% to $11.22 following second-quarter results.</li>
<li>MSCI Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSCI#NYSE">MSCI</a>) shares jumped 11.1% to $561.96 following better-than-expected second-quarter financial results.</li>
<li>QXO, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QXO#NASDAQ">QXO</a>) gained 10.3% to $66.27.</li>
<li>Beam Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>) gained 9% to $29.48. HC Wainwright &amp; Co. analyst Patrick Trucchio initiated coverage on Beam Therapeutics with a Buy rating and announced a price target of $80.</li>
<li>Iridium Communications Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRDM#NASDAQ">IRDM</a>) rose 8.5% to $28.11 after the company reported better-than-expected second-quarter EPS results.</li>
<li>Crown Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCK#NYSE">CCK</a>) gained 8.5% to $84.04 after the company reported better-than-expected second-quarter earnings and raised its FY24 EPS guidance above estimates.</li>
<li>MakeMyTrip Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMYT#NASDAQ">MMYT</a>) climbed 8% to $96.75 following better-than-expected quarterly earnings.</li>
<li>Inter Parfums, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPAR#NASDAQ">IPAR</a>) gained 8% to $137.34 after the company reported better-than-expected expected sales.</li>
<li>Owens &amp; Minor, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OMI#NYSE">OMI</a>) rose 8% to $16.51 as the company released preliminary second quarter 2024 financial results and signed a definitive agreement to acquire Rotech Healthcare for $1.36 billion in cash.</li>
<li>Mesoblast Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MESO#NASDAQ">MESO</a>) shares gained 8% to $8.15. Mesoblast recently started enrollment in Phase 3 trial of Rexlemestrocel-L for chronic low back pain.</li>
<li>Pentair plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PNR#NYSE">PNR</a>) gained 7.7% to $86.19 after the company reported better-than-expected second quarter financial results and revised its FY24 adjusted EPS guidance above estimates.</li>
<li>Park National Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRK#NYSE">PRK</a>) gained 7.4% to $182.78 following upbeat quarterly earnings.</li>
<li>Wheels Up Experience Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UP#NYSE">UP</a>) gained 7.1% to $3.46.</li>
<li>GE Aerospace (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GE#NYSE">GE</a>) shares surged 6.4% to $173.21 after the company reported better-than-expected second quarter adjusted EPS and raised its FY24 outlook.</li>
<li>SAP SE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAP#NYSE">SAP</a>) gained 6% to $0.2390 after the company reported second-quarter financial results.</li>
<li>Hims &amp; Hers Health, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NASDAQ">HIMS</a>) gained 5.6% to $21.51.</li>
<li>e.l.f. Beauty, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELF#NYSE">ELF</a>) surged 5.5% to $178.95.</li>
<li>Zions Bancorporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZION#NASDAQ">ZION</a>) rose 5.4% to $52.12 after posting better-than-expected quarterly results on Monday.</li>
<li>Brown &amp; Brown, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRO#NYSE">BRO</a>) gained 5.2% to $97.99 following upbeat quarterly earnings.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/07/39907046/best-buy-kroger-and-2-other-stocks-insiders-are-selling">Best Buy, Kroger And 2 Other Stocks Insiders Are Selling</a></li>
</ul>

BEAM

Hims & Hers Health, Inc. Class A Common Stock

HIMS

IPAR

IRDM

KREF

Danaher Posts Upbeat Earnings, Joins Spotify, MSCI, Owens & Minor And Other Big Stocks Moving Higher On Tuesday

DJ Owens & Minor Sees 2Q FY24 Revenue Of $2.651B -$2.671B; Adj EPS Of $0.32 - $0.36

DJ Owens & Minor Sees FY24 Adj EPS Of $1.40 - $1.70

DJ Owens & Minor Sees FY24 Revenue Of $105B - $10.9B

DJ Owens & Minor Sees FY24 Adjusted EBITDA Of $550M - $590M

Owens & Minor Signs Definitive Agreement To Acquire Rotech Healthcare For $1.36B In Cash

Citigroup analyst Daniel Grosslight upgrades Owens &amp; Minor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OMI#NYSE">OMI</a>) from Neutral to Buy and lowers the price target from $24 to $19.

Upgrades

Citigroup Upgrades Owens & Minor to Buy, Lowers Price Target to $19

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Merus (MRUS – Research Report), Twist Bioscience (TWST – Research...

Analysts Have Conflicting Sentiments on These Healthcare Companies: Merus (MRUS), Twist Bioscience (TWST) and Owens & Minor (OMI)

BofA's global contenders and defenders list

Fidelity Small Cap Discovery Fund Q2 2024 Review

Owens & Minor - Too Aggressive On The Dealmaking

Owens & Minor: Too Aggressive On The Dealmaking

Owens & Minor enter into partnership with Google Cloud to enhance QSight

Fidelity Small Cap Value Fund Q2 2024 Review

Cardinal Health Inc. is one of the leading wholesale distributors of pharmaceuticals, medical/surgical supplies and related products to a broad range of health care customers.

Cardinal Health, Inc. Dividend Stock Analysis

American Century High Income Fund Q2 2024 Commentary

These stocks are expected to benefit from the reshoring trend currently happening

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Owens & Minor

Owens & Minor (OMI) Forecast

Owens & Minor (NYSE:OMI) Stock, Quote.Headers.trade-ideas